- Home
- SANG vs ZNTL Comparison
SANG vs ZNTL Comparison
Compare SANG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SANG | ZNTL |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.0M | 156.7M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SANG | ZNTL |
|---|---|---|
| Price | $4.32 | $2.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 2.6K | ★ 670.4K |
| Earning Date | 05-07-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,425,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.08 | $1.01 |
| 52 Week High | $6.46 | $3.95 |
Technical Indicators
Market Signals| Indicator | SANG | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 50.40 |
| Support Level | $4.08 | $1.29 |
| Resistance Level | $5.36 | $2.69 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 18.50 | 39.17 |
Price Performance
Historical ComparisonAbout SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.